AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie pending Individual Lawsuits — Niaspan Antitrust [annual] (cases)
Form 10-K Note 15 Legal Proceedings & Contingencies
Latest, FY2025
6
Period ended Dec 31, 2025
Change on a year earlier
0.0%
6 in FY2024
History
6 years
Since FY2020
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Pending Individual Lawsuits — Niaspan Antitrust [annual] (cases) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | 0.0% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 6 | 0.0% | Form 10-K (filed 2025-02-14) ↗ |
| FY2023 | Dec 31, 2023 | 6 | +50.0% | Form 10-K (filed 2024-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 4 | 0.0% | Form 10-K (filed 2023-02-17) ↗ |
| FY2021 | Dec 31, 2021 | 4 | 0.0% | Form 10-K (filed 2022-02-18) ↗ |
| FY2020 | Dec 31, 2020 | 4 | – | Form 10-K (filed 2021-02-19) ↗ |
Cite this data
StockData. (2026). AbbVie Pending Individual Lawsuits — Niaspan Antitrust [annual] (cases), annual FY2020–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lit_niaspan
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.